Importance of transparency in assessing the feasibility of modeling rare disease
Med Decis Making
.
2015 Feb;35(2):143-4.
doi: 10.1177/0272989X14563081.
Epub 2014 Dec 12.
Authors
Scott J Johnson
1
,
Matthew R Davis
2
,
Si-Tien Wang
3
Affiliations
1
Medicus Economics, Milton, MA (SJJ)
2
Medicus Economics, LLC, Brookline, MA (MRD)
3
Medicus Economics, Cambridge, MA (STW)
PMID:
25505051
PMCID:
PMC4361492
DOI:
10.1177/0272989X14563081
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized / therapeutic use*
Cost-Benefit Analysis*
Drug Costs*
Hemoglobinuria, Paroxysmal / drug therapy*
Humans
Rare Diseases / drug therapy*
Substances
Antibodies, Monoclonal, Humanized